RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RioDerm-002 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RioDerm-002 overview
Rion overview
Rion is a clinical-stage regenerative medicine company. It develops purified exosome product (PEP), a biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. The company’s pipeline products in advanced wound care therapeutic area include RioDerm001, RioDerm002, RioDerm003 and RioDerm004; musculoskeletal therapeutic area comprise RioMSK001, RioMSK002; cardiovascular area include RioCard001; Pulmonary therapeutic area comprise RioPulm001; exosome drug delivery area include Cypher001, Cypher002 and eCypher001. Rion is headquartered in Rochester, Minnesota, the US.
For a complete picture of RioDerm-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
